Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMMUTEP LIMITED Board/Management Information 2011

May 2, 2011

65122_rns_2011-05-02_47c16fa8-6499-41bb-b880-533ba92b10cd.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

==> picture [144 x 38] intentionally omitted <==

ASX Code: PRR

Appointment of Joint Company Secretary

Tuesday 3[rd] May 2011

The Company wishes to announce that Mr Ian Bangs, Chief Financial Officer of Prima Biomed Limited, has been appointed Joint Company effective immediately.

ENDS

For further information please contact:

Mr Martin Rogers Chief Executive Officer Prima BioMed Ltd Ph: +61 (0) 428 268 357 E:[email protected] Website: www.primabiomed.com.au

Mr James Moses Investor and Media Relations Mandate Corporate Ph: +61 (0) 420 991 574 E: [email protected]

US Investor Relations

Ms Danielle Spangler Investor Relations The Trout Group Ph: +1 (646) 378 2900 E: [email protected]

About Prima BioMed

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology. Prima’s lead product is the CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is progressing toward eventual commercialisation in the United States, Australia, Europe and globally

.

The Company’s broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.

About CVac™ Ovarian Cancer Treatment

CVac™ is Prima BioMed’s lead product. It is of key importance as there is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate. CVac™ is a maintenance therapy administered post-surgery and post-chemotherapy to delay relapse and control metastases.

There are currently no products available as maintenance based therapies for ovarian cancer and the global market for ovarian cancer therapeutics was valued at US$2.1b in 2007 and is expected to total US$3.6b this year.

Regulatory approval and commercialisation of CVac™ is the core focus for Prima.

Prima BioMed Ltd , Suite 1, 1233 High St, Armadale, VIC 3143 Ph: +61 (0) 3 9824 5254 Fax: +61 (0) 3 9822 7735 www.primabiomed.com.au ABN: 90 009 237 889